<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: We previously discovered anti-p53 antibodies predating a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis in subjects at increased risk for liver, lung, breast, and <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, we reported a significant correlation (P &lt; 0.017) between p53 antibodies and p53 mutations in patients with late-stage <z:hpo ids='HP_0011459'>esophageal carcinoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Because others have reported p53 mutations and overexpression of p53 protein in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, we studied p53 antibodies in plasma of 88 serially endoscoped patients: 36 with Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath>, 23 with esophageal <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo>, 10 with esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, and 19 with <z:hpo ids='HP_0100633'>esophagitis</z:hpo> or <z:mpath ids='MPATH_458'>normal</z:mpath> esophagus </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We used enzyme immunoassay, immunoblotting, and immunoprecipitation assays for p53 antibodies; polymerase chain reaction, denaturant gradient gel electrophoresis, and sequencing for p53 mutations; and immunohistochemistry for p53 protein </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: p53 antibodies were detected in 4 patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, including 1 with <z:mpath ids='MPATH_589'>dysplasia</z:mpath> that later progressed to <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, and in 10 cancer patients (P = 0.002) (8 squamous and 2 <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>), 2 of whom (1 squamous, 1 <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>) had antibodies before <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was diagnosed </plain></SENT>
<SENT sid="5" pm="."><plain>Other patient groups were too small for informative statistical analysis </plain></SENT>
<SENT sid="6" pm="."><plain>Six antibody-positive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients had p53 mutations, whereas 2 patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and 1 with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with antibodies had p53 protein overexpressed in esophageal tissues </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> can develop p53 antibodies that may predate the clinical diagnosis of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
</text></document>